This study developed and validated a UV spectrophotometric approach for the simultaneous measurement of lamivudine (LAM) and zidovudine (ZID) in pharmaceutical dosage forms. This method use the simultaneous equation methodology to ascertain the absorbance at two wavelengths, 271 nm and 267 nm, corresponding to the peak absorption of LAM and ZID, respectively. The proposed methodology underwent statistical assessment to confirm its specificity, linearity, accuracy, precision, robustness, and adherence to the International Conference on Harmonization (ICH) standards. The technique exhibited linearity for both LAM and ZID within the 5–25 µg/ml concentration range, with correlation coefficients around 1. Precision studies demonstrate excellent repeatability with little intra- and inter-day variability, shown by low % RSD values. Results from recovery trials ranging from 98% to 102% demonstrated accuracy. The approach demonstrated sensitivity despite the moderate LOD and LOQ values. We exhibited our system's stability and consistency under many conditions throughout the robustness testing. The analysis of tablet formulations indicated that both medications were accurately quantified. The novel UV spectrophotometric technique provides a straightforward, sensitive, and cost-effective means of concurrently quantifying ZID and LAM in pharmaceutical formulations. It is useful for the routine evaluation of tablet dosage forms and quality assessment.
Keywords: Lamivudine, Zidovudine, Validation,Simultaneous and UV spectrophotoscopy.
How to cite this article: Ajankar NP, Pimple SS, Chaudhari PD, Deokate SB, Method development and validation for simultaneous estimation of Lamivudine and Zidovudine by UV spectrophotometric method. Int J Drug Deliv Technol. 2025;15(4): 1692-1700, DOI: 10.25258/ijddt.15.4.20